Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 10,873 matching trials from the live ClinicalTrials.gov search.

Filters: Nashville, Tennessee Clear all

Conditions: Postural Orthostatic Tachycardia Syndrome
Interventions: Blood Volume, Total Blood Volume, Exercise Capacity Test - Bicycle, Posture Study; Radiation · Procedure
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Lung Cancer
Interventions: Pembrolizumab, Epacadostat, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 15
States / cities: Anaheim, California • Whittier, California • Fort Myers, Florida + 12 more

Conditions: Renal Transplantation
Interventions: tacrolimus, CellCept, steroids (methylprednisone or prednisone); Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2007
U.S. locations: 29
States / cities: Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 24 more

Conditions: Sepsis
Interventions: Vitamin C, Thiamine, Hydrocortisone, Vitamin C Placebo, Thiamine Placebo, Hydrocortisone Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 43
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 30 more

Conditions: Breast Neoplasms, Prostate Neoplasms, Neoplasms, Squamous Cell, Melanoma, Mesothelioma, Pancreatic Neoplasms, Colorectal Neoplasms, Carcinoma, Renal Cell, Liver Neoplasms
Interventions: PF-06952229, Enzalutamide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 15
States / cities: Scottsdale, Arizona • Santa Monica, California • Boston, Massachusetts + 6 more

Conditions: Obesity, Pre-diabetes
Interventions: Empagliflozin 25 MG; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hypercholesterolemia, Dyslipidemia
Interventions: ABT-335 and rosuvastatin calcium, ABT-335, rosuvastatin calcium; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 760 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 168
States / cities: Birmingham, Alabama • Huntsville, Alabama • Ozark, Alabama + 135 more

Conditions: Multiple Myeloma
Interventions: AZD0120; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: Phoenix, Arizona • Duarte, California • Denver, Colorado + 10 more

Conditions: Pain
Interventions: Prialt (ziconotide); Drug
Lead sponsor: Elan Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 44
States / cities: Huntsville, Alabama • Northport, Alabama • Tucson, Arizona + 41 more

Conditions: Acute Heart Failure
Interventions: RLX030, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 6,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 105
States / cities: Huntsville, Alabama • Montgomery, Alabama • Tucson, Arizona + 76 more

Conditions: Primary Hyperoxaluria
Interventions: Oxabact OC5 - Oxalobacter formigenes HC-1, Placebo; Biological · Other
Lead sponsor: OxThera; Industry
Eligibility: 2 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Mouse Allergies, Mouse Sensitization
Interventions: Not listed
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Appendicitis
Interventions: Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin, Appendectomy; Drug · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 1,552 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 25
States / cities: Sylmar, California • Torrance, California • Aurora, Colorado + 14 more

Conditions: Crohn's Disease
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 5 Days to 16 Years
Enrollment: 1,813 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 25
States / cities: Los Angeles, California • San Francisco, California • Hartford, Connecticut + 20 more

Conditions: HIV Infections
Interventions: Calanolide A; Drug
Lead sponsor: Sarawak MediChem Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 9
States / cities: Miami, Florida • Vero Beach, Florida • Chicago, Illinois + 6 more

Conditions: Multiple Myeloma
Interventions: Oprozomib, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 17
States / cities: Encinitas, California • West Hollywood, California • Whittier, California + 13 more

Conditions: Heart Failure
Interventions: HNO Donor, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 24
States / cities: Tucson, Arizona • Gainesville, Florida • Tampa, Florida + 16 more

Conditions: CRC (Colorectal Cancer)
Interventions: Ruxolitinib, Regorafenib, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 57
States / cities: Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 54 more

Conditions: Head and Neck Neoplasms
Interventions: Pembrolizumab 200 mg, Radiotherapy 60 Gray, Radiotherapy 66 Gray, Radiotherapy 70 Gray, Cisplatin 100 mg/m^2; Biological · Radiation · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 714 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 68
States / cities: La Jolla, California • Los Angeles, California • Newport Beach, California + 56 more

Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions: Discussion, Goal Setting, Interview, Media Intervention, Medical Device Usage and Evaluation, Questionnaire Administration, Reward, Text Message-Based Navigation Intervention; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 15 Years to 20 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 76
States / cities: Mesa, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 58 more

Conditions: Adult Solid Tumor
Interventions: SQZ-eAPC-HPV, Pembrolizumab; Biological
Lead sponsor: SQZ Biotechnologies; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 9
States / cities: Scottsdale, Arizona • Duarte, California • Aurora, Colorado + 5 more

Conditions: Short Bowel Syndrome
Interventions: glepaglutide, Placebo; Drug
Lead sponsor: Zealand Pharma; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Chicago, Illinois • Rochester, Minnesota + 4 more

Conditions: Non-Eosinophilic Asthma
Interventions: AVTX-002, Placebo; Drug
Lead sponsor: Avalo Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 24
States / cities: Tucson, Arizona • Sacramento, California • Walnut Creek, California + 20 more

Conditions: Renal Transplantation
Interventions: Enteric-coated Mycophenolate Acid (EC-MPA), Mycophenolate Mofetil (MMF), Placebo MMF, Placebo EC-MPA; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 37
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 28 more

Search by objective public record fields.

Dietary Salt in Postural Tachycardia Syndrome

Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)

A Study to Compare Early Steroid Withdrawal and Long-Term Steroid Maintenance Therapy in Kidney Transplant Patients

Vitamin C, Thiamine, and Steroids in Sepsis

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot

A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

Prialt (Ziconotide) In Severe Chronic Pain

Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF

A Study to Evaluate the Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria

A Comparison of Skin Prick Tests, Clinical Symptoms, and Nasal Challenge Using a New Mouse Extract

The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial

Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease

A Study to Evaluate the Safety and Effectiveness of a New Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), (+)-Calanolide A, in HIV-Positive Patients Who Have Never Received Anti-HIV Treatment

A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma

Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure

Study of Ruxolitinib in Colorectal Cancer Patients

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study

Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)

A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.

A Study Designed to Compare the Tolerability of an Increased Dose of Enteric-coated Mycophenolate Acid (MPA) in Renal Transplant Patients Whose Dose of Mycophenolate Mofetil (MMF) Was Reduced Due to Gastrointestinal Symptoms